NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NasdaqGS: ACAD) securities between February 26, 2015 and March 11, 2015.
Click here to learn about the case: http://docs.wongesq.com/ACAD-Info-Request-Form-673. There is no cost or obligation to you.
The complaint alleges that the Company made false and misleading statements and/or failed to disclose material information regarding the timing of its submission of its New Drug Application to the FDA for Nuplazid.
On March 11, 2015, the Company announced it would delay submitting a New Drug Application for its drug Nuplazid. The Company also noted that Chief Executive Officer Uli Hacksell is retiring. Shares of ACADIA were down more than 20% on intraday trading the following day.
If you suffered a loss in ACADIA you have until May 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ACAD-Info-Request-Form-673.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.